Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TOP2A | P11388 | 11/20 | 0.67 |
| ▸ | TOP2B | Q02880 | 11/20 | 0.67 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.56 |
| ▸ | LMNA | P02545 | 2/20 | 0.55 |
| ▸ | HPGD | P15428 | 2/20 | 0.55 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.55 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.55 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.55 |
| ▸ | MAPT | P10636 | 1/20 | 0.55 |
| ▸ | PIK3CG | P48736 | 3/20 | 0.48 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.48 |
| ▸ | PIK3R1 | P27986 | 1/20 | 0.48 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9720558 | 0.91 | TOP2A (0.57) | TOP2ATOP2BKDM4EALDH1A1LMNA | |
| SCHEMBL9720481 | 0.91 | TOP2A (0.56) | TOP2ATOP2BKDM4EALDH1A1LMNA | |
| SCHEMBL9720542 | 0.90 | TOP2A (0.55) | TOP2ATOP2BKDM4EALDH1A1LMNA | |
| SCHEMBL9720548 | 0.90 | TOP2A (0.55) | TOP2ATOP2BKDM4EALDH1A1LMNA | |
| SCHEMBL9720463 | 0.89 | TOP2A (0.54) | TOP2ATOP2BKDM4EALDH1A1LMNA | |
| SCHEMBL9720480 | 0.89 | TOP2A (0.54) | TOP2ATOP2BKDM4EALDH1A1LMNA | |
| SCHEMBL9720505 | 0.88 | TOP2A (0.69) | TOP2ATOP2BKDM4EALDH1A1LMNA | |
| SCHEMBL9720493 | 0.87 | TOP2A (0.53) | TOP2ATOP2BKDM4EALDH1A1LMNA | |
| SCHEMBL7862768 | 0.87 | TOP2A (0.52) | TOP2ATOP2BKDM4EALDH1A1LMNA | |
| SCHEMBL9116286 | 0.87 | TOP2A (0.51) | TOP2ATOP2BKDM4EALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0394553-B1 | Use of fluorine containing pyridone carboxylic acid derivatives for preparing a medicament for the treatment of HIV infections | DAIICHI SEIYAKU CO (JP) | 1995-06-21 | — | — | EP | claimed |
| US-5075319-A | Bactericides | STERLING DRUG INC. (US) | 1991-12-24 | — | — | US | claimed |
| EP-0309789-A1 | 4-Oxo-3-quinolinecarboxylic acids useful as antibacterial agents and preparation thereof | STERLING WINTHROP INC. (US) | 1989-04-05 | — | — | EP | claimed |
| US-20090306035-A1 | Compounds and Methods for modulating the Silencing of a Polynucleotide of Interest | EMORY UNIVERSITY (US) | 2009-12-10 | — | — | US | disclosed |
| US-20090306035-A1 | Compounds and Methods for modulating the Silencing of a Polynucleotide of Interest | EMORY UNIVERSITY (US) | 2009-12-10 | — | — | US | disclosed |
| EP-0700399-B1 | 36-DERIVATIVES OF RIFAMYCINS AND THEIR USE AS ANTIMICROBIAL AGENTS | LEPETIT SPA (IT) | 2001-10-04 | — | — | EP | disclosed |
| US-5786350-A | CONDENSATION; HYDROLYSIS; DEPROTECTING | GRUPPO LEPETIT S.P.A. (IT) | 1998-07-28 | — | — | US | disclosed |
| EP-0700399-A1 | 36-DERIVATIVES OF RIFAMYCINS AND THEIR USE AS ANTIMICROBIAL AGENTS | GRUPPO LEPETIT S.P.A. (IT) | 1996-03-13 | — | — | EP | disclosed |
| EP-0394553-B1 | Use of fluorine containing pyridone carboxylic acid derivatives for preparing a medicament for the treatment of HIV infections | DAIICHI SEIYAKU CO (JP) | 1995-06-21 | — | — | EP | disclosed |
| WO-1994028002-A1 | 36-DERIVATIVES OF RIFAMYCINS AND THEIR USE AS ANTIMICROBIAL AGENTS | GRUPPO LEPETIT S.P.A. (IT) | 1994-12-08 | — | — | WO | disclosed |
| US-5169853-A | Antibacterial agents; administering to mammals for infection | STERLING DRUG INC. (US) | 1992-12-08 | — | — | US | disclosed |
| US-5075319-A | Bactericides | STERLING DRUG INC. (US) | 1991-12-24 | — | — | US | disclosed |
| EP-0417669-A2 | Pyridinyl-quinolone compounds, their preparation and use | STERLING WINTHROP INC. (US) | 1991-03-20 | — | — | EP | disclosed |
| EP-0394553-A2 | Use of fluorine containing pyridone carboxylic acid derivatives for preparing a medicament for the treatment of HIV infections | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 1990-10-31 | — | — | EP | disclosed |
| EP-0309789-A1 | 4-Oxo-3-quinolinecarboxylic acids useful as antibacterial agents and preparation thereof | STERLING WINTHROP INC. (US) | 1989-04-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090306035-A1 | Compounds and Methods for modulating the Silencing of a Polynucleotide of Interest | SNRPE, NSUN2, SNRPA | TOP2A 1071/4885TOP2B 998/4885KDM4E 3182/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.